Advancements in On-Body Drug Delivery Systems: Overcoming Challenges and Driving Innovation

April 10th, 2025 – 4pm (CET) / 10am (ET)

Advancements in On-Body Drug Delivery Systems: Overcoming Challenges and Driving Innovation

April 10th, 2025 – 4pm (CET) / 10am (ET)

Addressed Challenges

  • Handling volume and viscosity: Current delivery mechanisms, such as autoinjectors, are often unsuitable for administering high volumes or highly viscous drugs.
  • Patient adherence: The discomfort and extended time associated with certain delivery systems can negatively impact patient compliance and satisfaction
  • Commercialization complexities: The journey from engineering concept to market-ready device involves overcoming significant technical and regulatory hurdles.

Learning Objectives

  • Gain an understanding of the technological advancements behind OBDS, focusing on solutions for high-volume and viscous drug delivery.
  • Learn practical steps and strategies for rapidly optimizing an OBDS platform for clinical readiness.
  • Explore how OBDS can enhance patient outcomes and support differentiation in the pharmaceutical landscape.

Dr. Greg Moakes, PHD

Executive Vice President, Business Development

Greg Moakes is Executive Vice President of Business Development for LTS Lohmann Device Technologies LTD. Greg holds a Ph.D. In Chemistry from the Georgia Institute of Technology and an MBA from Southern Methodist University. His career had been focused on drug delivery, first specializing in solid implant dosage formulations and more recently high volume subcutaneous delivery via On-body Delivery Systems.
Read More >>>

<span>By ticking this box, you consent to receiving communications from LTS related to this topic and other products or services within their portfolio</span>

Dark